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ABSTRACT T cell activation through the T cell receptor is
necessary to achieve a specific and effective immune response.
We report here that stimulation of CD81 T cells through the T
cell receptor complex leads to de novo expression of the CD4
antigen on the cell surface that results in susceptibility of CD81
T cells to HIV infection. In addition, activation of peripheral
blood mononuclear cells from HIV-infected individuals results in
the appearance of double-positive CD41yCD81 T cells, which
become infected by endogenous HIV. HIV DNA sequences could
be detected in uncultured and sorted mature CD31CD81 T cells
from HIV1 individuals. These results suggest a new mechanism
by which HIV could attack the immune system and may help to
explain the CD81 T cell defects in AIDS patients.
Despite mounting a strong humoral and cell-mediated immune
response against HIV, the host’s immune system is able to only
partially control the infection. HIV RNA can be detected in
plasma of patients at all stages of disease, with the highest
levels observed during initial infection and late stages of
disease (1). The generation of viral variants (escape mutants)
(2), proviral integration, and infection of key immunocompe-
tent CD41 T cells and phagocytes may explain how HIV
escapes immune surveillance. Furthermore, the effects of HIV
proteins (such as gp120 and Tat), as well as elevation of
a-interferon further impairs the immune response by suppress-
ing the proliferative response of uninfected T cells (3–10).
However, the inability of the immune system to overcome HIV
infection is still incompletely understood. For instance, CD81
cytotoxic T lymphocytes (CTL) are thought to play an impor-
tant role in the control of viral infection through both HIV-
specific cytotoxic activity (11–14) and release of soluble factors
capable of suppressing HIV replication (15, 16). In fact, the
onset of AIDS is associated with a decline in both the number
of CD81 T cells and specific anti-HIV cytotoxic activity
(17–20). Although mature CD81 T cells are not considered
prime targets for HIV infection, several reports have demon-
strated that, under certain circumstances, HIV can infect these
cells (21–27). However, no satisfactory explanation could be
generated as to how HIV may gain entry into CD81 T cells. In
the present work we provide evidence that infection of mature
peripheral blood CD81 T cells by HIV is mediated through the
CD4 molecule, whose gene expression is induced following
activation through the T cell receptor (TCR) complex. These
results will strengthen the notion that CD81 T cells can
become infected by HIV both in vitro and in vivo and provide
additional explanations to HIV-associated immunological de-
terioration.
MATERIALS AND METHODS
Cells, Culture Conditions, and Flow Cytometry. Peripheral
blood mononuclear cells (PBMC) were obtained from healthy
donors after centrifugation over FicollyPaque gradient (Phar-
macia). PBMC were depleted of CD41 T cells by using
anti-CD4 coated magnetic beads (Immunotech, Westbrook,
ME). Efficiency of CD4 depletion was monitored by flow
cytometry. CD4 depleted cells (107) were stimulated either
with 1 mgyml phytohemagglutinin (PHA)-P (Sigma), 1 mgyml
staphylococcal enterotoxin B (SEB) (Sigma), 200 ngyml anti-
CD3 (Immunotech), or 1 mgyml toxic shock syndrome toxin 1
(Sigma) in a total volume of 10 ml of RPMI 1640 medium
supplemented with 10% fetal bovine serum and antibiotics
(complete medium). Twenty-four hours poststimulation, 20
unitsyml of interleukin-2 (Boehringer Mannheim) were added
to the cultures and 6 days later cytofluorometric analyses were
performed. Cells were simultaneously stained with phyco-
erythrin (PE)-conjugated anti-CD4 and fluorescein isothio-
cyanate (FITC)-conjugated anti-CD8 mAb (Becton Dickin-
son). Control aliquots were stained with FITC- or PE-
conjugated mouse IgG1. In all experiments, 10,000 events were
accumulated and analyzed. For phenotypic analysis of double
positive (DP) cells, CD4-depleted PBMC (0% CD82CD41)
were stimulated with 1 mgyml SEB for 7 days and stained with
PE-conjugated anti-CD4 and one of the following FITC-
labeled antibodies: anti-CD2, -CD3, -CD25, -CD26, -CD27,
-CD28, -CD45RO, -CD45 RA, -CD69, -CD71, -CD122, -HLA-
DR, -TCR ab chains (Becton Dickinson), -Vb 3, -Vb 6.1, Vb
13.6, Vb 14, Vb 17, and Vb 21.3 (Immunotech).
CD4 induction was also studied by using the interleukin
2-dependent human T lymphotropic virus, type I-immortal-
ized cell lines 67.I (21), CD8 U-1, and clone D7 derived from
the latter. CD4 was induced by stimulating with 1 mgyml SEB
for 4 days and expression studied by flow cytometry following
staining with anti-CD4 and anti-CD8 as described above.
Immunoprecipitation and Western Blot Analysis. PBMC
depleted from CD4 were activated with SEB for 6 days. CD81
T cells (25 3 106), of which 24% were expressing CD4, were
lysed and CD4 immunoprecipitated by using rabbit anti-CD4
antibodies and protein A Sepharose. The immunoprecipitate
was resolved by SDSyPAGE electrophoresis and proteins
transferred to nitrocellulose. Membranes were probed for both
CD4 and p56lck. After washing, the membranes were probed
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with peroxidase-labeled secondary antibodies and signal de-
tected by chemiluminescence (Amersham). SEB (107) acti-
vated CD41 T cells were used as positive controls.
Kinetics of CD4 Protein and mRNA Expression in Activated
Mature CD81 T Cells. CD4-depleted PBMC from two healthy
donors were activated with PHA or SEB. Cells were stained for
CD4 and CD8 at various days (from day 0 to day 27) and
percentage of CD81 T cells expressing CD4 calculated.
For CD4 mRNA studies, PBMC from three healthy donors
were depleted of CD41 T cells by using magnetic beads coated
with anti-CD4 antibodies (Immunotech). The CD4 depleted
cells were stained for both CD8 and CD4 and further purified
by cell sorting. Sorted cells were lysed in Trizol and RNA
extracted. CD4 depleted cells were also stimulated with 1
mgyml SEB for 6 days before phenotyping for CD8 and CD4
coexpression and RNA extraction. CD41 T cells were used as
positive controls. The RNA was extracted and analyzed for
CD4 and glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) expression by reverse transcriptase (RT)–PCR. The
following primer pairs were used: CD4 59-GGAGTCCCTT-
TTAGGCACTTGC-39 and 59-AAGACAGTGCATGTC-C-
AGGTG-39; G3PDH 59-ACCACAGTCCATGCCATCAC-39
and 59-TCCACCACCCT-GTTGCTGTA-39. After 30 cycles
of amplification, 15% of the products were resolved by elec-
trophoresis, transferred to nylon membranes and hybridized
with specific 32P-labeled oligonucleotide probes. The CD4
probe sequence is 59-GCCACTCAGGGAAAGAAAGT-39
and the G3PDH probe sequence is 59-CACGGAAGGCCAT-
GCCAGTGAGCTTC-CCGT-39. After hybridization, the
membranes were washed and exposed to x-ray films.
Infection of Activated CD81 T Cells by HIV-1. CD4-
depleted PBMC were stimulated with PHA for 7 days. Phe-
notypic analysis indicates that 96.5% of the cells were CD81 T
cells, of which 24% coexpressed the CD4 molecule.
CD82CD41 (1.6%) and CD42CD82 (1.9%) represented the
remaining cell populations. Cells (107) were centrifuged,
washed with PBS and resuspended in 0.1 ml PBS-1% fetal
bovine serum with or without 5 mgyml OKT4A or 5 mgyml
anti-CD28 and incubated for 1 hr at 4°C. After an additional
wash, cell pellets were treated with HIV-IIIB (1 ng p24
equivalent) for 1 hr at 4°C then washed trice with PBS and
resuspended in complete medium supplemented with 10
unitsyml interleukin 2. Corresponding cultures were also con-
ditioned with 2 mgyml OKT4A or 2 mgyml anti-CD28. Cell-
free supernatants were collected at various days and assayed
for p24 antigen.
Intracellular expression of HIV-1 antigen in CD81 T cells
was detected by partial cytoplasmic membrane solubilization
(0.1% Triton X-100 in PBS) of paraformaldehyde-fixed in-
fected cells by using FITC-labeled anti-HIV p24 (Coulter) and
PE-labeled anti-CD8 (Becton Dickinson). Controls consisted
of infected cells treated as above and incubated with matching
isotypes FITC- and PE-labeled mAb.
For electron microscopy studies, PHA-activated CD4-
depleted PBMC were treated with HIV-1 for 6 days. Cells
(99% CD81) were surface labeled with anti-CD8, washed
twice with PBS followed by incubation with gold-labeled
(10-nm particle diameter) goat anti-mouse antibodies. Cells
were fixed in 2.5% glutaraldehyde and processed for electron
microscopy.
HIV DNA PCR. PBMC from HIV-infected individuals with
CD4 counts ranging from 50 to 300 were isolated and parts
thereof were immediately frozen to 270°C. The remainder
were surface stained with PE-labeled anti-CD3 and FITC-
labeled CD8 antibodies. Mature T cells (i.e., CD31CD81)
were sorted out from the remaining cells and stored frozen
until used. Precautions to avoid contamination included sep-
arate chambers for DNA isolation and reactions setup. Crude
DNA (20 ml) was added to 80 ml of PCR mixture containing
100 pmol of each oligo (SK38 and SK39), 200 mM dNTP, and
2.5 units of TAQ gold enzyme (Perkin–Elmer). A negative
control consisting of water along with the PCR mix were
included in each run. An initial denaturation step of 10 min at
95°C was performed, followed by 45 cycles of 1 min 94°C
denaturation, 1 min at 55°C for annealing, and 1 min at 72°C
for elongation. Thirty microliters of the PCR mixture was then
mixed with a 32P-labeled (105 cpm) internal probe (SK19). The
mixtures were heated to 95°C for 5 min and incubated at 55°C
for 15 min. Ten microliters was then electrophoresed through
a 10% nondenaturing Triszborate EDTA gel and exposed to
x-ray films. All samples were also amplified by using a primer
pair for the G3PDH gene to show the presence of DNA and
the absence of inhibitors.
RESULTS
Activation Through the TCR Induces Cell Surface CD4
Expression in Mature CD81 T Cells. While studying T cells, we
observed that cellular activation induces cell surface expres-
sion of CD4 molecules at the cell surface of CD81 T cells.
PBMC depleted of CD41 T cells were stimulated with mito-
gens, including the plant lectin PHA, the bacterial superanti-
gen SEB, and the anti-CD3 mAb OKT3. As shown in Fig. 1A,
resting CD8 T cells do not express CD4 antigen (Upper Left).
However, 7 days after activation with such mitogens, expres-
sion of CD4 could be detected, by using two-color flowcyto-
metric analysis, at the cell surface of CD81 T cells. The
percentage of CD81 T cells expressing the CD4 molecule
varied from 26–59%. Similar results were obtained with
another bacterial superantigen, toxic shock syndrome toxin 1
(data not shown). Although variations were observed in the
intensity of CD4 expression between different PBMC donors,
CD4 expression on the surface of CD81 T cells upon cell
activation was consistently observed. CD4 induction by mito-
gens was also observed in unfractionated PBMC (not shown).
We next determined whether the CD4 receptor expressed in
CD81 T cells was functionally associated with its signaling
enzyme, the p56lck tyrosine kinase. The CD4 antigen was
immunoprecipitated from SEB-activated CD4-depleted
PBMC (,0.5% CD31CD41) and probed by Western blot for
CD4 and p56lck. As shown in Fig. 1B, CD4 could be immu-
noprecipitated from CD81CD41 DP cells and these CD4
molecules were physically associated with p56lck, suggesting
that CD81 T cells express a functional CD4 capable of
signaling through this kinase. SEB-activated CD41 T cells
were used as positive control.
Because only a portion of SEB-activated CD81 T cells
acquire the CD4 antigen after activation we proceeded to
phenotype these DP cells (Fig. 1C). These DP cells express
common activation markers (CD25, CD26, CD27, CD28,
CD69, CD71, CD122, and HLA-DR) as well as T cell markers
(CD2, CD3, and TCR ab chains). Interestingly, the majority of
the DP CD81CD41 cells were also coexpressing TCR Vb
chains that are reactive with SEB (Vb 3, Vb 14, and Vb 17)
while low percentages of CD41yCD81 coexpression were
observed with SEB unreactive Vb s (6.1, 13.6, and 21.3),
suggesting that direct activation by SEB is required for CD4
induction. Consistent with this observation, conditioned media
from PHA- or SEB-stimulated CD81 T cells were not found
to induce CD4 on resting CD81 T cells (data not shown),
suggesting that a soluble factor released by activated cells is not
responsible for CD4 induction. In addition to primary cells,
similar results were obtained with SEB-activated human T
lymphotropic virus type I-immortalized CD81 T cell lines
expressing SEB-reactive Vb TCR chains (data not shown).
These cell lines express major histocompatibility complex class
II antigens thereby bypassing the need for professional antigen
presenting cells to obtain proper activation stimuli. Although
these cell lines express minimal levels of CD4 under basal
conditions, upon activation with SEB, the vast majority of




















CD81 T cells were found to express the CD4 antigen. A
selective expansion of the few DP initially present is unlikely
as these cultures were kept for short periods of time (3–4 days)
after stimulation.
Kinetics of CD4 Expression in CD81 T Cells. Next, we
determined the kinetics of CD4 induction on CD81 T cells
following mitogen activation. As shown in Fig. 2A, no DP cells
were observed until day 3 poststimulation. The maximum
number of DP cells, varying between 10 and 30% in this
experiment, was observed on day 6. DP cells (range 7–17%)
were observed for up to 27 days poststimulation, at which time
cultures were terminated. We also studied CD4 mRNA in both
resting CD81CD42 and SEB activated CD81 T cells obtained
from three normal individuals. To ensure that no residual
CD41 T cells remained, we extensively purified single positive
CD81 T cells by both magnetic bead selection and cell sorting.
The resulting cells (0% CD41) were lysed and RNA extracted.
In parallel, CD4-depleted PBMC were activated with SEB for
6 days, phenotyped by flow cytometry for CD4 and CD8
coexpression followed by RNA extraction. CD41 T cells were
used as positive control. Flow cytometry profiles of cells before
and after SEB activation from one donor, representative of
three different donors, are shown in Fig. 2B. We then analyzed,
by RT-PCR, the expression of the CD4 mRNA along that of
the housekeeping G3PDH gene in these three cell populations.
As shown in Fig. 2B, CD4 mRNA can be detected in mature
CD41 T cells while no expression of CD4 mRNA could be
detected in freshly isolated CD81CD42 cells. In contrast,
SEB-activated CD81 T cells contained an easily detectable
level of CD4 mRNA. The G3PDH mRNA amplification was
used to assess the relative amount of RNA used for amplifi-
cation. A minus RT reaction tube was included for each sample
to assess for possible contamination by genomic DNA. In such
samples, no amplicons were detected. The inability to detect
CD4 mRNA in resting CD81CD42 T cells, by using the
FIG. 1. (A) CD4 antigen induction in activated mature CD81 T
cells. Resting, or 6-day-old PHA-P (1 mgyml), SEB (1 mgyml), or
anti-CD3 (200 ngyml) activated cells were stained for both CD4 and
CD8 antigen expression. Control aliquots were stained with FITC- or
PE-conjugated irrelevant mouse IgG1. (B) Association of p56lck to
CD4 in activated mature CD81 T cells. PBMC depleted CD41 T cells
were activated with SEB for 6 days. CD81 T cells (25 3 106), of which
24% were expressing CD4, were lysed and CD4 immunoprecipitated.
Following SDSyPAGE electrophoresis, proteins were transferred to
nitrocellulose and probed for both CD4 and p56lck. SEB (107)
activated CD41 T cells were used as positive controls. (C) Phenotypic
analysis of CD81 T cells coexpressing CD4. Seven-day-old SEB
activated CD4-depleted PBMC (0% CD82CD41) were simulta-
neously stained with PE-conjugated anti-CD4 and various FITC-
conjugated mAb. The percentage of cells expressing a specific marker
was determined after acquisition and analysis of 10,000 events.
FIG. 2. (A) Kinetics of de novo surface CD4 expression of activated
CD81 T cells. CD4-depleted PBMC were obtained from two healthy
donors and activated with PHA or SEB. Cells were stained for CD4
and CD8 at various days (from day 0 to day 27) as described in
Materials and Methods. Percentages of CD81 T cells expressing the
CD4 antigen were determined after analysis of 10,000 events. (B) CD4
mRNA levels before and after CD81 T cell activation. Resting CD41,
resting CD81 and SEB activated CD81 T cells from three healthy
donors were analyzed for CD4 protein and CD4 mRNA expression.
(Top) The CD4yCD8 flow cytometry profiles of one of the donors,
which is representative of the two other donors. RNA from each
category (resting CD41, resting CD81, and activated CD81) was
extracted and subjected to RT-PCR for both CD4 mRNA and G3PDH
mRNA expression. For each sample, a minus RT control was included
to monitor for possible genomic contamination.




















sensitive PCR technique, confirms previous work of others
(22, 28), and supports the notion of a transcriptionally con-
trolled CD4 gene.
CD4-Mediated Infection of Activated Mature CD81 T Cells.
We next determined the susceptibility of activated CD81 T
cells to HIV infection. Seven-day-old PHA-activated CD81
cultures (99% CD81) were treated with HIV-IIIB in the
presence or the absence of an anti-CD4 or anti-CD28 mAb. As
shown in Fig. 3A, HIV was capable of productively infecting
activated CD81 T cells, as determined by p24 antigen produc-
tion, and this infection could be abrogated by treatment with
anti-CD4 mAb but not with anti-CD28 mAb, suggesting that
infection proceeded through a CD4 receptor-mediated path-
way. Furthermore, just as the case with CD41 T cells, HIV
infection of DP cells was associated with reduction of CD4
expression. Twelve days postinfection both uninfected and
HIV-infected DP cells were stained for CD8 and CD4 anti-
gens. As previously reported for CD41 T cells (29, 30),
HIV-IIIB was able to decrease CD4 expression on CD81 T
cells (Fig. 3B). Whether this finding reflects selective depletion
of CD4-expressing cells or receptor down-regulation remains
to be established. In addition, infection of CD81 T cells by
HIV was conclusively established by p24 antigen staining and
CD8-ImmunoGold-labeled electron microscopic analyses. Ap-
proximately 20% of CD81 T cells were positive for intracel-
lular HIV p24 (Fig. 3C), indicative of a productive type of
infection. These results were also confirmed by detection of
HIV budding particles from ImmunoGold-labeled CD81 T
cells. Budding and more mature HIV particles could be found
associated in 10% of CD81 gold-labeled cells in agreement
with the number of DP cells from this particular experiment
(not shown).
Next, we determined whether in vitro activation of PBMC
from HIV-infected patients with PHA or SEB would induce
DP cells and subsequently whether these DP cells could be
infected by endogenous HIV. PBMC from HIV-infected
patients with circulating CD4 counts ranging from 5–1,200 per
ml were isolated and stimulated with mitogens. Between days
12–19 of culture, when HIV-1 p24 could be detected in the
culture supernatant, cells were doubly stained by using PE-
conjugated anti-CD4 and FITC-conjugated anti-CD8 mAb. As
shown in Fig. 4A, 79% of the CD81 T cells from one
HIV-infected individual coexpressed CD4. The other six do-
nors had a percentage of DP cells ranging from 18–90%. Next,
we determined whether the DP cells could be infected by
endogenous HIV. Duplicate cultures were also stained with
PE-conjugated anti-CD8 and FITC-conjugated anti-HIV
FIG. 3. (A) Infection of activated mature CD81 T cells by HIV-1.
Seven-day-old PHA-activated CD4-depleted PBMC were infected
with HIV-1 IIIB in the absence or the presence of OKT4A or
anti-CD28. At various times after infection, cell-free supernatants
were collected and stored until HIV-1 p24 antigen determination.
Results (mean 6 SD) were calculated from triplicate cultures and are
representative of two separate experiments. (B) Disappearance of
CD41CD81 T cells following HIV-1 infection. Twelve days post-
HIV-1 infection of activated CD81 T cells, cells were stained for both
CD8 and CD4. Cells from uninfected cultures were simultaneously
analyzed for CD4 and CD8 markers. (C) Intracellular detection of
HIV p24 in CD81 T cells. Six-day-old PHA-activated CD4-depleted
PBMC were treated with HIV-1 for 5 days and analyzed for cell
surface CD8 and intracellular HIV-1 p24 antigen expression.
FIG. 4. (A) Analysis of DP cells in activated PBMC cultures from
HIV-infected individuals. PBMC from HIV-infected patients were
isolated and stimulated with PHA. On days 12–19, cells were stained
and analyzed for CD4 and CD8 coexpression. (B) Infection of CD81
T cells by endogenous HIV. On days 12–19 poststimulation cells were
stained for both CD8 and HIV gp120 expression and analyzed by flow
cytometry. Results from one donor, representative of five, is pre-
sented. (C) Infection of CD81 T cells from HIV-infected individuals
with HIV-1 IIIB. PBMC from HIV-infected individuals were stimu-
lated for 12–19 days with PHA and then treated with HIV-1 IIIB
(multiplicity of infection, 0.1). After five days, cells were stained for
surface expression of both CD8 and HIV-1 gp120 and analyzed by flow
cytometry. (D) HIV DNA detection in PBMC and sorted CD31CD81
T cells from HIV-infected individuals. DNA from PBMC or
CD31CD81 sorted T cell population from 12 HIV-infected individ-
uals was isolated and subjected to PCR for the presence of HIV DNA
sequences. G3PDH gene was amplified as positive control and water
as negative control. (Top) The dot plot profile of one donor, repre-
sentative of 12, before and after sorting of CD31CD81 T cells.




















gp120 mAb. In most patients studied (5y7) we could demon-
strate the presence of HIV-infected CD81 T cells. The two
patients from which we could not show evidence of infection
of CD81 T cells may be explained by the fact that we could not
rescue HIV from these two patients as determined by p24
antigen production. An example of HIV-infected CD81 T cells
from one patient is shown in Fig. 4B. A low proportion of the
CD81 T cells (1–3%) were found to express HIV gp120 at their
surface. Similar results were obtained when cells were stained
for intracellular HIV p24 (data not shown) confirming that
detection of gp120 on the cell surface was not due to virus
bound to the cell surface. These DP cells could also be infected
with exogenously added HIV-IIIB (Fig. 4C). Five days follow-
ing infection with HIV-IIIB (multiplicity of infection, 0.1)
7–12% of CD81 T cells were expressing HIV gp120.
Because CD4 expression can be induced by T cell activation,
one should expect to find a portion of the CD81 T cells to be
infected by HIV in vivo. To test this hypothesis, we isolated
PBMC from 12 HIV1 individuals, selectively isolated their
CD31CD81 mature T cells by sorting and analyzed these
samples for HIV DNA sequences (Fig. 4D). For detection, we
used the PCR technique with conditions that allowed detec-
tion of as low as one to five integrated copies of HIV (data not
shown). An example from one sample of PBMC before and
after sorting for CD31CD81 is shown in Fig. 4D. Typically,
,1% contaminating CD31CD82 were present in the sorted
samples. After PCR and hybridization, a positive signal was
detected in all of the unfractionated PBMC samples. In the
sorted CD31CD81 T cells, HIV DNA was detected in 10 out
of 12 samples. PCR was also performed by using a primer pair
specific for the G3PDH gene to show the presence of ampli-
fiable DNA.
DISCUSSION
The results presented here show that a significant proportion
of activated CD81 T cells are induced to express the CD4
molecule at their surface. This is the first conclusive demon-
stration that CD4 can be expressed by CD81 T cells under
physiological conditions, i.e., through direct triggering of the
TCR. Previous observations had shown CD4 induction by
treating cells with 5-azacytidine (31), by infecting cells with
human herpesvirus 6 (23) or by stimulation with the plant
lectin Con A (32). DP cells were tested for the presence of
human herpesvirus 6, which may have accounted for CD4
induction, and no evidence of infection could be demonstrated
(data not shown).
Although CD4 induction on CD81 T cells has yet to be
studied in classical T cell activation, i.e., by TCR interaction
with peptides presented by major histocompatibility complex
class 1 molecules, similar results are expected as SEB, toxic
shock syndrome toxin 1 and anti-CD3 mAb can mimic acti-
vation of T cells through TCR engagement. It is noteworthy
that a low percentage (1–3%) of DP cells can be observed in
the peripheral blood of healthy individuals (33). Although
these cells are commonly referred to as immature DP cells, our
results suggest that, more than likely, these cells may represent
activated peripheral blood CD81 T cells.
To better understand CD4 gene expression in mature CD81
T cells, we have generated a series of plasmid constructs in
which the expression of the luciferase reporter gene is driven
by genetic elements controlling CD4 gene expression. Such
elements include the CD4 promoter (34), the CD4 enhancer
(35), and the CD4 silencer (36–38). All of these CD4 con-
structs, when transfected in CD41 T cells such as Jurkat,
showed considerable activity (not shown). These constructs
were therefore tested for inducibility by SEB following trans-
fection in the 67.I CD81 T cell line. Although basal activity was
detected, no significant increase in reporter gene activity could
be detected following SEB activation (data not shown). As a
positive control, the cells were transfected with the pGL3
control plasmid in which luciferase gene expression is driven
by the simian virus 40 promoter. Thus, the mechanisms leading
to CD4 gene expression in mature CD81 T cells remains
unclear. It is possible that our reporter constructs, although
active in CD41 T cells, may not adequately mimic the genetic
organization of the CD4 gene. The CD4 gene is complex with
an enhancer element located 6.5 kb upstream of the first exon
(35) and a silencer element located within the first intron
(36–38). Characterization of the human CD4 silencer indicates
that this element is active in vivo and much less effective in
suppressing heterologous promoter in vitro, suggesting that the
simple presence of this regulatory sequence may not be
sufficient to observe the silencing effect (38). In all likelihood,
CD81 T cell activation turns on the CD4 gene through
silencing of the silencer. Further studies are needed to char-
acterize the factors interacting with this regulatory element.
Although it is not yet known whether this phenomenon has
any role in the physiology of cytotoxic T cells, the relevance of
this observation to HIV pathogenesis is of obvious impor-
tance. In HIV-infected individuals, reactive cytotoxic T cells
recruited to kill HIV-infected cells would, as a consequence of
specific antigenic activation, express the CD4 antigen and
become targets for HIV infection. Moreover, CD81 T cells
reactive against any pathogens, once activated, may become
susceptible to HIV infection. A recent report indicates that
CD81 T cells from macaques can be infected in vivo by simian
immunodeficiency virus (39). A proportion of these CD81 T
cells were also found to coexpress the CD4 antigen that, in
most likelihood, is the mean by which simian immunodefi-
ciency virus gained entry into these cells. In the past, it has
been difficult to show the presence of HIV in CD81 human T
cells. The reasons for this may be accounted for by the less
sensitive detection methods used or by the fact that positive
results were thought to arise from contaminating CD41 T cells
in the samples. However, more recent studies indicate that
HIV can be found in uncultured human CD81 T cells (40, 41).
Our results are supportive of such findings.
To gain entry into cells, HIV-1 must bind and interact with
at least two distinct molecules: CD4 and a seven transmem-
brane G-protein coupled chemokine receptor. Most nonsyn-
cytium-inducing primary HIV-1 isolates and monocytotropic
strains of HIV-1 interact with the CCR5 chemokine receptor
(42–44) while syncytium-inducing or T cell tropic HIV-1
strains bind to CXCR4 (45). CCR5 is expressed on both CD41
T lymphocytes and monocytesymacrophages (46) while
CXCR4 is predominantly expressed on T cells (47). Resting
and activated primary CD81 T lymphocytes do also express
CXCR4 and CCR5 (46, 47), suggesting that both syncytium-
inducing and nonsyncytium-inducing strains of HIV-1 can
infect these cells, once the CD4 gene has been turned on. Our
data on infection of activated CD81 T cells by HIV-1 IIIB (Fig.
3) and Ba-L (not shown) correlates with CXCR4 and CCR5
coreceptor expression.
HIV infection is not dormant at any time and many infected
cells are continuously producing virus leading to a perpetual
immune solicitation of HIV reactive cells spanning several
years (1, 48). During this time, HIV-specific CD81 T cells
could be eliminated, both directly by HIV infection and
indirectly by immune exhaustion, leaving a gap in the reper-
toire of HIV-reactive cells leading to uncontrolled viral ex-
pression as seen in the late stage of the disease. Infection of
CD81 T cells by HIV is likely to happen during all stages of
disease with perhaps the greatest rate occurring during the
initial phase of infection when an intact repertoire of reactive
cells is present. However, because of the high number of CD41
T cells present, and the low percentage of susceptible CD81 T
cells, the infection of CD81 T cells may go undetected with
current technology. Interestingly, the disappearance of HIV
CTL during the early phase of infection was recently reported




















(49). These results suggest that CTL depletion does occur after
HIV infection and massive antigenic stimulation is undoubt-
edly responsible for specific CTL clone exhaustion. However,
the potential of HIV to infect and kill activated CD81 T cells
can only accentuate the turnover rate of reactive clones and
further contribute to CTL exhaustion.
In summary, several hypotheses such as anergy, apoptosis
and extensive activationydifferentiation have been made to
explain the depletion of HIV-specific CTL observed in AIDS.
The results presented here suggest that HIV may impair the
effector arm of the immune system through an additional
mechanism, by direct infection and thus selective depletion of
HIV reactive CTL.
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